45 Items

per page
Set Descending Direction
Catalog No.
Product Name
Product Information
Product Citation
  1. c-Met Inhibitor

    AMG 208 is a novel c-Met inhibitor that inhibits the ligand-dependent and ligand-independent activation of c-Met, inhibiting its tyrosine kinase activity.
  2. c-Met inhibitor

    BMS-777607 is a MET tyrosine kinase inhibitor that binds to c-Met protein, or HGFR, preventing binding of HGF and disrupting the MET signaling pathway.
  3. c-Met inhibitor

    BMS-794833 is a potent ATP competitive inhibitor to Met and VEGFR-2 with IC50 of 1.7 and 15 nmol.
  4. c-Met inhibitor

    c-Met inhibitor JNJ-38877605 selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways.
  5. c-Met inhibitor

    MGCD265 is a multitargeted tyrosine kinase inhibitor that binds to and inhibits the phosphorylation of several RTKs, including the c-Met receptor (HGFR); the Tek/Tie-2 receptor; VEGFR types 1, 2, and 3; and MST1R.
  6. c-Met Inhibitor

    PF-04217903 is a novel c-Met/hepatocyte growth factor receptor tyrosine kinase inhibitors.
  7. ALK/ c-Met inhibitor

    PF-2341066 (Crizotinib) is an inhibitor of the c-Met kinase and the NPM-ALK. PF-2341066 inhibited cell proliferation in ALK-positive ALCL cells (IC50s=30 nM).
  8. c-Met Inhibitor

    PHA665752 is a small-molecule inhibitor of c-Met/HGF/SF signaling.
  9. c-Met Inhibitor

    SGX-523 is an orally bioavailable small molecule, specifically binds to c-Met protein, or HGFR, preventing binding of HGF and disrupting the MET signaling pathway.
  10. c-Met inhibitor

    SU11274 is a Met tyrosine kinase inhibitor.
  11. VEGFR inhibitor

    XL184 free base (Cabozantinib) is a small molecule designed to inhibit multiple receptor tyrosine kinases, specifically MET and VEGFR2.
  12. c-MET inhibitor

    Foretinib (GSK1363089), a multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces Anoikis, and impairs ovarian cancer metastasis.
  13. c-Met inhibitor

    AMG-458 is a potent inhibitor of c-Met with an IC50 value of 60nM and displays selectivity against VEGFR2.
  14. IGF-1R inhibitor

    BMS-754807 is an efficacious, orally active growth factor 1 receptor/insulin receptor family-targeted kinase inhibitor that may act in combination with a wide array of established anticancer agents.
  15. c-Met inhibitor

    ARQ-197 is a selective inhibitor of the c-Met receptor tyrosine kinase
  16. c-MET Inhibitor

    INCB28060, a novel inhibitor of c-MET kinase. INCB28060 exhibits picomolar enzymatic potency and is highly specific for c-MET with more than 10,000-fold selectivity over a large panel of human kinases. This inhibitor potently blocks c-MET phosphorylation and activation of its key downstream effectors in c-MET-dependent tumor cell lines.
  17. C-Met inhibitor

    NVP-BVU972 is a selective MET inhibitor.
  18. c-Met Inhibitor

    EMD-1214063 is an inhibitor of MET tyrosine kinase with potential antineoplastic activity. It binds to MET tyrosine kinase and disrupts MET signal transduction pathways, which may induce apoptosis in tumor cells overexpressing this kinase.
  19. multiple receptor tyrosine kinases inhibitor

    Cabozantinib S-malate (XL184 S-malate) is a potent multiple receptor tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.
  20. c-Met/VEGFR-2 inhibitor

    E7050 (also known as golvatinib is an orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factor receptor-2) tyrosine kinases with potential antineoplastic activity.
  21. c-Met inhibitor

    MK-8033 is a novel and specific dual ATP competitive c-Met/Ron inhibitor (IC50=1 nM Wt c-Met) under investigation as a treatment for cancer.
  22. c-Met Inhibitor

    MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.
  23. c-MET inhibitor

    LY2801653 is a potent, orally bioavailable, small-molecule inhibitor of c-MET kinase(Ki= 2 nM).
  24. c-Met/VEGFR inhibitor

    Altiratinib is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling, cell growth and migration as compared with a HGF antagonist in vitro.
  25. c-Met inhibitor

    Volitinib is an orally bioavailable inhibitor of the c-Met receptor tyrosine kinase with potential antineoplastic activity.
  26. c-Met inhibitor

    c-Met inhibitor 1 is an inhibitor of the c-Met receptor signaling pathway useful for the treatment of cancer including gastric, glioblastoma, and pancreatic cancer.
  27. MET inhibitor

    LY2801653 dihydrochloride is a potent, orally bioavailable, small-molecule inhibitor of c-MET kinase(Ki= 2 nM).
  28. c-Met Inhibitor

    PF-04217903 methanesulfonate is a selective ATP-competitive c-Met inhibitor with IC50 of 4.8 nM, susceptible to oncogenic mutations (no activity to Y1230C mutant).
  29. MET/VEGFR-2 inhibitor

    BMS-817378 is a novel prodrug of the dual Met/VEGFR-2 inhibitor BMS-794833.
  30. c-Met inhibitor

    NPS-1034 is a dual Met/Axl inhibitor with IC50 of 48 nM and 10.3 nM, respectively.
  31. c-Met/NPM-ALK inhibitor

    Crizotinib is inhibitor of the c-Met kinase and the NPM-ALK.
  32. c-Met inhibitor

    c-Met inhibitor 2 is a potent compound that has activity against cancers dependent upon Met activation and also has activity against cancers as a VEGFR inhibitor.
  33. MET/Axl inhibitor

    Glesatinib hydrochloride is an inhibitor of the MET and Axl receptor tyrosine kinase pathways, which drive tumour growth when altered.
  34. MET inhibitor

    AMG 337 is an oral, small molecule, ATP-competitive, highly selective inhibitor of the MET receptor.
  35. c-Met tyrosine kinase inhibitor

    Tivantinib is a highly selective c-Met tyrosine kinase inhibitor with a Ki of 355 nM.
  36. tyrosine kinase inhibitor

    Ningetinib is a multi-kinase inhibitor that inhibits c-Met, VEGFR2/KDR, and Axl with IC50s value of 19, 37, and 11 nM, respectively.
  37. c-Met inhibitor

    JNJ-38877618 is a novel potent, highly selective, orally bioavailable c-Met tyrosine kinase inhibitor with Kd of 1.2, 2.1 and 21 nM for WT, M1250T and Y1235D mutants MET, respectively.
  38. c-Met inhibitor

    Glumetinib (SCC244) is a potent and highly selective c-Met kinase inhibitor with an IC50 of 0.42 nM. Glumetinib shows antitumor activity and a superior safety margin.
  39. ALK/MET inhibitor

    Ensartinib (X-396) is a potent and dual ALK/MET inhibitor with IC50s of <0.4 nM and 0.74 nM, respectively.
  40. AXL/c-Met inhibitor

    CEP-40783 is a potent, selective and orally available inhibitor of AXL and c-Met with IC50 values of 7 nM and 12 nM, respectively.
  41. c-Met/HGFR inhibitor

    TAS-115 mesylate is a potent VEGFRand hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase inhibitor, with IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectively.
  42. MET, AXL/MER, and FGFR1/2/3 inhibitor

    S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3 with IC50 values below 20 nM.
  43. multi-targeted tyrosine kinase inhibitor

    Amuvatinib hydrochloride (MP470 hydrochloride) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Kit, PDGFRα, Flt3, c-Met and c-Ret.
  44. c-Met/Axl/Ron/Tyro3 inhibitor

    BMS 777607 is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3 with IC50s of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM, respectively.
  45. MET/VEGFR2/MER inhibitor

    XL092 is an ATP-competitive inhibitor of multiple RTKs including MET, VEGFR2, AXL and MER, with IC50 values in cell-based assays of 15, 1.6, 3.4, and 7.2 nM respectively.

45 Items

per page
Set Descending Direction